Wegovy vs Mounjaro vs Ozempic: Compared by a GMC-Registered GP

Written by Dr. Simon Khela MBChB MRCGP, GMC Registered Doctor

Last reviewed: 16-07-2026

_________________________________________________________________________

‍

Rarely has a category of medication generated as many patient questions in as short a time as this one. Barely a week goes by in clinic without someone asking me, often slightly apologetically, to explain the difference between Wegovy, Mounjaro and Ozempic. Many arrive having already decided which one they want, usually based on something they saw online or heard from a friend, only to be surprised when I explain that one of those three names isn't actually licensed for weight loss in the UK at all.

That confusion isn't the patient's fault. These medications have been discussed so widely, and often so loosely, in the media and on social platforms that the practical details- what they're licensed for, how they're taken, what they cost, and what the side effects actually look like in practice- have got lost somewhere along the way. This article sets out to correct that, clearly and honestly, from a clinical perspective rather than a marketing one.

Quick Answer: What's the Difference Between Wegovy, Mounjaro and Ozempic?

Wegovy and Ozempic both contain the same active ingredient, semaglutide, but they are licensed differently in the UK:

• Wegovy is licensed specifically for weight management.
• Ozempic is licensed only for type 2 diabetes; using it purely for weight loss is an off-label use that most reputable UK prescribers are cautious about, partly due to ongoing supply issues for people who need it for diabetes control.
• Mounjaro contains a different active ingredient, tirzepatide, which acts on two hormone pathways rather than one (GLP-1 and GIP). It's licensed in the UK for both type 2 diabetes and weight management.

In clinical trials, tirzepatide has generally produced greater average weight loss than semaglutide-based treatments, though individual results vary considerably. All three are given as a weekly injection, not a tablet, despite "Mounjaro tablets" and "Ozempic pills" being common search terms. There is a related oral semaglutide medication, but it's a separate product with a different brand name, explained further down.

What Are These Medications, and How Do They Actually Work?

All three belong to a class of medicines that mimic naturally occurring gut hormones involved in appetite and blood sugar regulation.

• Semaglutide (the active ingredient in both Wegovy and Ozempic) is a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone released after eating that slows stomach emptying, increases feelings of fullness, and helps regulate insulin release. By mimicking this hormone at a higher, more sustained level than the body produces naturally, semaglutide reduces appetite and helps people eat less without the same degree of hunger.
• Tirzepatide (the active ingredient in Mounjaro) works on the same GLP-1 pathway but also activates a second hormone receptor, GIP (glucose-dependent insulinotropic polypeptide). This dual action is thought to explain why tirzepatide has shown somewhat stronger average results in trials compared with semaglutide alone, although it's a relatively newer medication with a shorter track record.

These aren't appetite suppressants in the stimulant sense. They don't create a "high" or override hunger through sheer willpower. They change the underlying signalling between the gut, pancreas and brain, which is why many patients describe the effect as simply "not thinking about food as much" rather than a dramatic change in mood or energy.

Wegovy vs Mounjaro vs Ozempic: Comparison Table

‍

Trial results vary by study design and population, and individual outcomes are rarely identical to average figures. These numbers give a general sense of scale, not a personal prediction.

Is Ozempic Actually Licensed for Weight Loss in the UK?

This is one of the most important points made in almost every consultation on this topic, and it's the one that most surprises patients. Ozempic is licensed in the UK exclusively for the treatment of type 2 diabetes. It is not licensed as a weight loss treatment, even though it contains the same ingredient as Wegovy, which is.

• Prescribing Ozempic purely for weight loss in someone without diabetes is an off-label use, which the MHRA and NHS have both raised concerns about, partly on clinical grounds and partly because of the impact on supply for people who rely on it to manage their diabetes.
• There have been documented UK-wide shortages of semaglutide products over the past few years, and prescribing Ozempic off-label for weight loss has been identified as one contributing factor.
• If Ozempic is prescribed specifically for weight loss rather than diabetes, this is outside the medication's intended and tested use, which affects the clarity of dosing guidance and monitoring recommendations.

Wegovy, by contrast, has been through clinical trials and regulatory approval specifically for weight management, at doses designed for that purpose. This distinction is raised not to alarm anyone who may already be taking Ozempic, but because patients deserve to understand it clearly before choosing between medications, rather than assuming the three names are interchangeable options with the same regulatory standing.

Are Wegovy, Mounjaro and Ozempic Tablets or Injections?

A large number of people search for "Mounjaro tablets", "Ozempic pills" or "Wegovy tablets", so it's worth addressing directly: as marketed in the UK, Wegovy, Mounjaro and Ozempic are all given by subcutaneous injection, typically once a week, using a pre-filled pen designed for self-injection at home. None of them currently exists as an oral tablet under those brand names.

There is a genuinely oral form of semaglutide, sold under the brand name Rybelsus, which is a tablet taken daily rather than a weekly injection. It's licensed in the UK for type 2 diabetes. It isn't the same product as Wegovy or Ozempic in form, and it isn't currently licensed for weight management on its own in the way Wegovy is, though this is an area of ongoing research and worth checking at the point treatment is being considered, since licensing changes periodically.

For most patients, the injection itself is less of a barrier than expected. Guidance on how to inject Mounjaro correctly covers the fine needles and self-injection technique in detail, and most people become comfortable with the process within the first few doses. That said, needle anxiety is a real and valid concern for some patients, and it's a legitimate factor to raise with whoever is prescribing treatment.

Mounjaro Side Effects

The side effects most commonly reported with Mounjaro relate to the digestive system, particularly in the early weeks of treatment or after a dose increase:

• Nausea, which tends to be the most common side effect, especially when starting or increasing dose
• Diarrhoea or constipation, sometimes alternating
• Reduced appetite (an intended effect, though sometimes more pronounced than expected)
• Fatigue
• Reflux or indigestion
• Injection site reactions, usually mild

Less common but more serious risks include gallbladder problems (including gallstones), pancreatitis, and, rarely, a worsening of diabetic retinopathy in people with pre-existing diabetes. Mounjaro is not recommended during pregnancy or breastfeeding, and it carries specific precautions for people with a personal or family history of certain thyroid cancers, which is one of several reasons a proper medical assessment, rather than simply ordering the medication online, matters before starting treatment. Rushing the dose escalation is one of the most common causes of severe nausea and vomiting seen in practice, which is why gradual titration matters.

Wegovy Side Effects

Wegovy's side effect profile is broadly similar to Mounjaro's, given that both act on related hormone pathways, though Mounjaro's dual mechanism means the two aren't identical in every respect:

• Nausea, particularly during dose escalation
• Diarrhoea and constipation
• Vomiting, in a minority of patients, especially if the dose is increased too quickly
• Headache
• Fatigue
• Abdominal pain or bloating

As with Mounjaro, gallbladder disease and pancreatitis are recognised, uncommon risks. Wegovy also carries the same precautions around thyroid cancer history and pregnancy. Side effects tend to be most noticeable in the first four to eight weeks, and for most patients who persist through gradual titration, they settle considerably, though a minority do stop treatment due to ongoing gastrointestinal symptoms.

Ozempic Side Effects

Because Ozempic and Wegovy share the same active ingredient, their side effect profiles overlap substantially:

• Nausea and vomiting
• Diarrhoea or constipation
• Low blood sugar (hypoglycaemia), particularly when combined with other diabetes medications such as sulfonylureas or insulin, which is specific to Ozempic's use in diabetes management
• Injection site reactions
• Fatigue

The hypoglycaemia risk is worth highlighting separately, since it's specific to how Ozempic is typically used, alongside other glucose-lowering medications, in people with type 2 diabetes. This is a further practical reason why using Ozempic off-label for weight loss, outside proper diabetes management and monitoring, isn't recommended without a clear clinical reason and appropriate oversight.

Difference Between Weight Loss Tablets and Injections

Beyond Rybelsus, patients sometimes ask whether other "weight loss tablets" work in a similar way to Mounjaro, Wegovy or Ozempic. Broadly, older weight loss tablets, such as orlistat, work through a completely different mechanism, reducing fat absorption in the gut, rather than affecting appetite hormones. They tend to produce more modest average weight loss and come with different side effects, mainly gastrointestinal, related to undigested fat passing through the digestive system.

The injectable GLP-1 and GIP medications discussed in this article generally produce more substantial average weight loss in trials than older oral options, though they require ongoing injections, closer monitoring, and are typically more expensive, at least in the private market. A broader overview of semaglutide weight loss injections covers this comparison in more depth. The right choice depends on individual health factors, tolerance of injections, cost, and whether there's an underlying condition, such as type 2 diabetes, that changes which options are appropriate or available on the NHS.

Wegovy, Mounjaro and Ozempic Price in the UK

Private prescription costs for these medications vary between providers and change periodically, partly due to fluctuating manufacturer pricing and periods of national shortage, including recent Mounjaro supply and price changes reported across the UK market. As a general guide at the time of writing:

• Mounjaro private prescriptions in the UK typically range from around £150 to £250 per month, depending on dose and provider
• Wegovy private prescriptions typically range from around £150 to £220 per month, depending on dose
• Ozempic, where prescribed for its licensed use in diabetes, is usually funded via NHS prescription for eligible patients rather than paid for privately for weight loss

These figures are indicative only and should be checked directly with a prescriber, since prices shift with supply and dose strength. On the NHS, access to Wegovy and Mounjaro for weight management is currently limited and phased, generally via specialist weight management services or, more recently, through a gradual rollout in primary care for people who meet specific clinical criteria. Most people currently accessing these medications for weight loss in the UK are doing so through private prescription, which is why proper clinical assessment beforehand matters so much.

Common Myths and Misconceptions

“They're all basically the same drug.”

Not accurate. Wegovy and Ozempic share an active ingredient, but Mounjaro is chemically different and works on an additional hormone pathway. Their licensing, intended use and side effect emphasis also differ.

“You can just buy whichever one you want online.”

These are prescription-only medicines requiring proper medical assessment, including a check of medical history, current medications, and suitability, before treatment starts. The MHRA warning on counterfeit weight-loss injections highlights the real safety risks of buying these medications without a genuine prescribing assessment, including counterfeit products. A wider safety guide to weight-loss pens covers this in more detail.

“The weight loss is permanent.”

For most patients, weight regain is common after stopping treatment unless it's paired with sustained lifestyle changes. These medications are best thought of as one part of a longer-term approach, not a standalone permanent fix.

“Mounjaro and Ozempic come in tablet form.”

As discussed above, this isn't currently the case for either brand in the UK. Confusion often arises from Rybelsus, a related but distinct oral semaglutide tablet licensed for diabetes.

“There are no real side effects if you just start on a low dose.”

Starting low and titrating slowly reduces the likelihood and severity of side effects considerably, but it doesn't eliminate them. Some degree of nausea or digestive change is common, especially in the first two months.

Who Shouldn't Take These Medications, and When to Speak to a GP

These medications aren't appropriate for everyone. They're generally avoided or used with particular caution in people who:

• Are pregnant, breastfeeding, or planning pregnancy in the near future
• Have a personal or family history of certain thyroid cancers (medullary thyroid carcinoma) or Multiple Endocrine Neoplasia syndrome type 2
• Have a history of pancreatitis
• Have significant, unexplained gastrointestinal symptoms that haven't been assessed
• Have an eating disorder, given the appetite-suppressing effect these medications produce

Before starting any of these treatments, a full review of medical history, current medications, and, often, baseline blood tests, including kidney function and, where relevant, HbA1c and a cholesterol check, matters, since weight loss and improved metabolic health frequently affect cardiovascular risk markers as well. This isn't a box-ticking exercise. It's about making sure the treatment is genuinely appropriate for that individual, rather than assuming one size fits all because it worked well for someone else.

If you're considering any of these medications, a proper private GP appointment or a structured assessment through a health check-up beforehand gives a much clearer picture of whether you're a suitable candidate, and which of the available options fits your particular health profile, rather than choosing based on which name is most talked about online.

Frequently Asked Questions about Weight Loss